Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas

NCT05011058 is registered in ClinicalTrials.gov with Viracta Therapeutics, Inc. as lead sponsor.

NCT NCT05011058
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05011058 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
Lead sponsor
Viracta Therapeutics, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
May 28, 2021
Completion date
January 31, 2025
Enrollment
102 (actual)
Sites
62

Conditions

As the registry lists them; a condition with its own page is linked.

ebv related ptcl, nos, ebv-positive dlbcl, nos, ebv-related hodgkin lymphoma, ebv-related lymphoproliferative disorder, ebv-related non-hodgkin lymphoma, ebv-related ptld, epstein-barr virus associated lymphoma